Pharmacological interventions aimed at repolarising ATMs from M1 to M2 phenotypes, or at least attenuating M1-associated inflammatory actions, are significant for improving insulin sensitivity and ameliorating obesity-related metabolic complications [147,152]. The gene discussed is INS; the disease is obesity due to melanocortin 4 receptor deficiency.